雲南白藥(000538.SZ):擬以不超112.29億元戰略入股上海醫藥 持股達18.02%
格隆匯5月11日丨雲南白藥(000538.SZ)公佈,根據上海醫藥2021年度非公開發行A股股票預案,上海醫藥擬向特定對象非公開發行不超過(含)852,626,796股A股股票,募集資金總額不超過(含)約143.84億元。
公司擬作為戰略投資者、以現金方式參與認購上海醫藥2021年度非公開發行的665,626,796股A股股票,認購金額不超過(含)人民幣約112.29億元。上海醫藥向公司非公開發行股票的數量以中國證監會最終核準發行的股票數量為準。根據上海醫藥此次非公開發行安排,預計此次交易完成後,公司將持有上海醫藥665,626,796股A股股票,佔上海醫藥發行後總股本的18.02%。
此次雲南白藥認購上海醫藥非公開發行A股股票的價格為16.87元/股,為定價基準日前二十個交易日上海醫藥A股股票交易均價的80%。
同時,雲南白藥作為戰略投資者擬根據與上海醫藥籤署的《戰略合作協議》的約定向上海醫藥提名1名執行董事候選人、1名非執行董事候選人以及1名監事候選人。根據《上市規則》的規定,公司基於實質重於形式的原則,將認定上海醫藥將為公司的關聯方。因此,此次交易構成關聯交易。
此次交易前,公司專注於藥品生產制造、新藥研發、藥品流通服務、中藥資源開發、營養保健、健康護理等業務領域。通過本次交易達成雙方的戰略合作,公司能夠借助上海醫藥的優質平台和產業資源,進一步放大雲南白藥作為行業領軍企業所擁有的規模、渠道和品牌優勢,把握產業整合的重要機遇,拓展主營業務規模、拓展既有產業布局、提升整體運營效率,通過雙方未來在醫藥健康領域廣泛而深入的合作,有利於上市公司主營業務的持續穩定發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.